Product Information
LISINOPRIL 30 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.0541 per EA under NDC 65862004105. Its NADAC has been published 17 times since Jul 30, 2025.
FDA first approved this application on Feb 22, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862004105
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
11/19/2025
Active Ingredients
LISINOPRILApproval Type
Generic (ANDA)
FDA Application
ANDA077622FDA Approved
2/22/2006
TE Code
AB
On Market Since
2/22/2006
Pharmacological Classes
Price Statistics
The NADAC for LISINOPRIL 30 MG TABLET has been published 17 times since Jul 30, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0541 per EA |
|---|---|
| All-time high | $0.0551 (Aug 13, 2025) |
| All-time low | $0.0540 (Sep 17, 2025) |
| 52-week high | $0.0541 |
| 52-week low | $0.0540 |
| Median price | $0.0540 |
| Average price | $0.0544 |
| Largest weekly change | -1.7% (Sep 17, 2025) |
| Weeks tracked | 17 |
| Tracking since | Jul 30, 2025 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
+0.1%
3Y
N/A
5Y
N/A
All
-1.9%
Last surveyed Nov 19, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lisinopril market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LISINOPRIL 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LISINOPRIL 30 MG TABLET, manufactured by Aurobindo Pharma Limited, is $0.0541 per EA (NDC 65862004105), effective Nov 19, 2025.
How has the price of LISINOPRIL 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for LISINOPRIL 30 MG TABLET has held within roughly two percent of its current level. It has been tracked across 17 weekly CMS publications since Jul 30, 2025.
What are the highest and lowest recorded NADAC prices for LISINOPRIL 30 MG TABLET?
Since Jul 30, 2025, the NADAC for LISINOPRIL 30 MG TABLET has ranged from a low of $0.0540 (Sep 17, 2025) to a high of $0.0551 (Aug 13, 2025), with a median of $0.0540 per EA.
Are there cheaper alternatives to LISINOPRIL 30 MG TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LISINOPRIL 30 MG TABLET, is $0.0520 per EA — about 4% below LISINOPRIL 30 MG TABLET.
Who manufactures LISINOPRIL 30 MG TABLET?
LISINOPRIL 30 MG TABLET (NDC 65862004105) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.